Services & Solutions
/
Drug Metabolism & Pharmacokinetics (DMPK)
/
In Vitro Services
/
Drug-Drug Interaction
The evaluation of the potential of candidate drugs to undergo drug-drug interactions is an important undertaking in drug development.
Our team of scientists evaluate the potential of the drug candidate to act as a perpetrator (determination of the IC50 or Ki of inhibition of CYP or other enzymes of interest) and victim (reaction phenotyping) of drug-drug interactions.
- CYP Inhibition
- CYP Induction
- CYP Reaction Phenotyping
- Reaction Phenotyping of non-CYP enzymes (UGT, SULT, FMO, aldehyde oxidase, MAO, etc.)
- Inhibition of non-CYP enzymes (UGT, SULT, FMO, aldehyde oxidase, MAO, etc.)
Data obtained from these studies will be included in product label to ensure the safe use of drugs
Kinetics of Inactivation of CYP2C19 by ABC
| Replicate # | kinact(min-1) | KI(μM) | kinact/KI (mL/min/µmol) |
|---|---|---|---|
| 1 | 0.04742 | 6.584 | 7.20 |
| 2 | 0.04813 | 5.466 | 8.81 |
| 3 | 0.04679 | 6.128 | 7.64 |
| Mean ± SD | 0.04745±0.00067 | 6.059±0.562 | 7.88±0.83 |
Discover the following In Vitro services at Frontage
Metabolite Profiling and Identification
A key in supporting the development of your drug candidate.
Kinetics & Metabolic Stability
Evaluating pharmacokinetic parameters is essential for determining drug dosing and frequency.
Drug-Drug Interaction
Drug-drug interaction and evaluation is an important undertaking in drug development.
Permability and Transporters
Comprehensive transporter services to support projects from discovery to development.
Protein Binding and Blood Cell Partitioning
A determinant of both drug elimination and drug pharmacological activity.
Resources To Consider
journal
Drug-drug Interaction Study of CYP3A4 Inhibitors with Colchicine Oral…
The primary objective of the study was to compare the pharmacokinetic (PK) variables of pl…
